Member Info for Bella6532

And this is on top of DVs announcement last week...
"We continue to see a rise in interest in our real-time wastewater monitoring solutions from several governments and these installations follow on from last week's announcement of £2.2m of Microtox® PD shipments.'

Deepverge is using Avacta affimers in their Microtox PD and BT (breath test) technology and both are linked to a sophisticated AI data collection/monitoring system.

And this is on top of DVs announcement last week...
"We continue to see a rise in interest in our real-time wastewater monitoring solutions from several governments and these installations follow on from last week's announcement of £2.2m of Microtox® PD shipments.'

Deepverge is using Avacta affimers in their Microtox PD and BT (breath test) technology and both are linked to a sophisticated AI data collection/monitoring system.

Ophidian..thanks for the reply.

Your contacts still positive?

My guess is they are still working through large orders as a result of 30 Sept presentation to Pharma/Investors and we won't get news until they're done. Happens all the time on AIM. Brokers call the shots on timing of news. AIM is not so regulated at main markets.

This is from the Aug LFT RNS update...
'The Company has recently appointed Calibre Scientific, a global distributor of diagnostic and life science products, as the first distributor for the test in the UK and European Union, and is progressing multiple commercial opportunities with distributors and end users in Europe, UK, Asia and elsewhere.'

How does this work with regard to the Medusa19 exclusivity agreement. Calibre is non-exclusive but Medusa have pretty much global exclusivity unless Medusa and Avacta are negotiating deals jointly...house accounts etc

gje306...you missed off supply chain issues. The kits are made up of all sorts of bits and pieces and one missing bit or items not coming through in sufficient volume will have an effect on either manufacturing assembly or finished product packaging.

Being mopped up nicely...

It looks like they're taking the UK information from this list..
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices

It looks like they've added..'Soft Tissue Sarcoma'..

From the product leaflet on their site:

'The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test Kit is a chromatographic immunoassay intended for the qualitative detection of the nucleocapsid protein antigen from
SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab,saliva or nasal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset. It only recognizes the N protein and cannot detect the S protein and its mutation structure. The test provides preliminary test results. Negative results do not preclude SARS-CoV-2 infection and they cannot be used as the sole basis for treatment or other management decision. For in vitro diagnostic use only. Summary The novel coronaviruses belong to the ß genus.COVID-19 is an acute respiratory
infectious disease. People are generally susceptible. Currently, the patients infected by novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation periodis 1 to 14 days,mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases. Principle The Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test Kit is composed of novel Coronavirus monoclonal antibody 2 and goat anti- mouse IgG polyclonal antibody fixed in the nitrocellulose membrane and Novel Coronavirus monoclonal antibody 1 latex-labeled fixed in the release pad. The kit tests Novel Coronavirus SARS-CoV-2 N antigen in human
nasopharyngeal swabs , oropharyngeal swabs ,saliva or nasal swabs with the principle of double antibody sandwich method by latex immunochromatography. When a specimen is added to the sample well, the sample is first mixed with the colored latex-labeled novel coronavirus monoclonal antibody 1 on the release pad, and then migrate on the nitrocellulose membrane. If SARS-CoV-2 N protein antigen presents in the sample, these antigens will bind to coronavirus monoclonal antibody 1 labeled with color latex forming antigen antibodies complex. This complex migrates through nitrocellulose membrane by capillary action. When the complex is captured by the SARS-CoV-2 monoclonal antibody 2 to form a red colored band in the T line, which is a positive result. If no antigen presents in the sample, there will be no red band appearing in the testing region, this is a negative result. The internal control (C band) fixing with goat anti-mouse antibody should exhibit a red band regardless of whether antigen presents in the test.'

'Richard Hughes and Mahmud Kamani, Founders of Medusa19 commented:

“We immediately recognised the global opportunity to distribute the simple and unique saliva-based COVID-19 rapid test being developed by Avacta based on their unique and powerful Affimer platform.

Medusa19 will enable end-to-end supply of these tests on a global basis subject to regulatory approval and manufacturing capacity which will be key. The enormous, world-wide demand for these tests requires a robust and scalable platform which we are in the process of creating. Hundreds of millions of tests are required and this demand will continue.'

Is Jinwodu going to be manufacturing our test as well as distributing it???
If Medusa have global rights to distribute our test they're going to need access to huge production capacity and China appears to be the only place able to offer this.
However, this does fly in the face of UK made...or are they hanging their hat on the affimer being UK made...
All will be revealed no doubt in due course...

And the work through continues...

Recent Share Trades for Avacta (AVCT)
Date Time Trade Prc Volume Buy/Sell Value
22-Oct-21 17:09:04 122.00 69,491 Unknown* 84.78k O
22-Oct-21 14:04:03 119.00 1,940 Sell* 2,309 O
22-Oct-21 14:04:03 119.00 -16,819 Sell* -20.01k O
22-Oct-21 14:04:03 119.00 4,796 Sell* 5,707 O
22-Oct-21 14:04:03 119.00 9,606 Sell* 11.43k O
22-Oct-21 14:04:03 119.00 477 Sell* 567.63 O
22-Oct-21 16:42:32 122.00 15,724 Unknown* 19.18k O
22-Oct-21 16:42:32 122.00 -15,724 Unknown* -19.18k O
22-Oct-21 16:42:32 122.00 15,724 Unknown* 19.18k O
22-Oct-21 16:36:56 120.00 3,931 Sell* 4,717 O

Geez...you guys are so funny...
Why would any company give a blow by blow concerning their day to day goings on when they are in competition with many other companies...

It's new tech...it's in the hands of others to approve...we don't do the manufacturing...we only sell to large house accounts and our distributors will do the marketing/sales...

Above all we don't want to be grouped in with the likes of Innova...better to wait a little longer to get full approvals not time limited emergency usage etc...

I'm loving all the green..keep it up guys...when you're here we all know something good is happening behind the scenes...order filling comes to mind..be it Jupiter trying to get out or someone else trying to get in...
How many of you will still be here when the news starts to break...

Page 2
'We applied to the Medicines and Healthcare products Regulatory Agency (MHRA) for an ‘exceptional use’ authorisation for the Innova LFD, and Orient Gene independently applied. The MHRA provided the authorisations to fill short-term gaps in the market, as no CE-marked self-tests were available. Both devices have subsequently been deployed in the UK, with the authorisations providing the regulatory authority for deployment.
The process of applying for an exceptional use authorisation requires the applicant to provide data to support the intended use of the LFD test. In these instances, we, on behalf of Innova, and Orient Gene provided the MHRA with data in support of applications for LFD tests that use a lower nasal swab and are intended for use on asymptomatic individuals. Furthermore, we conducted field service evaluations before deciding to deploy the LFD tests. The results of these evaluations can be found at www.gov.uk/government/publications/lateral-flow-device-performance-data.
It is important to note that the approval for the exceptional use authorisations is time-limited and is granted on the condition that a CE mark for self-testing, the standard regulatory approval process, will be obtained by Innova and Orient Gene.
The UK was ahead of the world in embracing LFDs, and they continue to be a central part of the Government’s strategy to combat COVID-19. These innovative technologies will allow infectious individuals to be identified, isolate and prevent onward transmission, reducing illness and the burden on the NHS and saving lives.
I hope this reply is helpful.
MAGGIE THROUP'

Maggie Throup MP
Parliamentary Under Secretary of State for Vaccines and Public Health

The following letter was sent to me via OP my MP
'15 October 2021
Dear Owen,
Thank you for your correspondence of 25 June on behalf of your constituent, Ms XXXXXXXXXXX, about the manufacturing and validation of COVID-19 testing kits. I apologise for the delay in replying.
I am grateful to you for raising Ms XXXXXXX’s concerns.
Alongside the symptomatic testing service, NHS Test and Trace is using rapid-testing technologies for asymptomatic individuals and to improve our detection of positive cases. Roughly one in three people who have the virus do not have symptoms and could therefore be spreading the disease without knowing it.
We are committed to boosting UK manufacturing and demonstrated this with the award of a contract for 20 million devices to Derby-based test manufacturer, SureScreen Diagnostics. These lateral flow device (LFD) tests were the first British tests to be validated in the laboratory by Public Health England.
Collaboration between industry and Government continues to be a priority and we are hugely grateful to all the manufacturers and suppliers that have come forward to offer their assistance in producing LFD tests.
The valuable partnerships being created with companies such as SureScreen Diagnostics are further contributing to the resilience of the UK, both through supporting the work of UK diagnostics manufacturers and by harnessing the possibilities opened up by rapid regular testing.
Our Dynamic Purchasing System, a procurement tool that allows qualifying suppliers to compete for contracts, will diversify the supply of LFD tests through fair and transparent competition. Further information can be found at www.gov.uk by searching for ‘national technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’.
To be purchased by the department, LFD tests need to have been validated by Porton Down and must have regulatory approval in the form of either an exceptional use authorisation (EUA) or a European conformity (CE) mark. None of the products for self-testing with Medicines and Healthcare products Regulatory Agency EUA approval or a CE mark is currently manufactured in the UK.
The process of deploying an LFD test, such as those supplied by Innova and Orient Gene, into the mass-testing programme is robust, consisting of detailed validation and evaluation of the LFD prior to deployment. LFD tests have been rigorously tested and are safe for regular use; any suggestion otherwise is inaccurate and potentially harmful.
All LFD tests that we procure undergo an extensive clinical evaluation by Oxford University and Porton Down. This is to confirm that the tests display performance characteristics desirable for mass-population and community-based testing. The desirable performance characteristics are high specificity and sensitivity against the viral loads associated with infectiousness, and the work performed at Porton Down assesses the clinical performance of LFD tests. '

Cont...

Goodlooking...'All MM Im afraid. 38 shares bought at 1.32 after 5.00 last night totally distorted the share price.'

It could be a sign...news after lunch/after 1.30....

ha ha

Hun...I said I'd hold you to it...haha...
Still best part of the day left so no problems just yet...xx

28jaczar01...agree and I suspect it's linked to the fact AS presented to a bunch of investors/pharma on 30 Sept.
They are having to pull out all the tricks to get their hands on shares in any volume without crashing the SP. They're trying to maintain the SP in a steady bandwith.
If you look at the weekly candle chart it looks like we've been kept within said bandwith since around 8 August.

It's all about order filling.. they're still working a large order...